-

Alka-Seltzer® Launches New Hangover Relief Product in a Musical Collaboration with T-Pain

Remixed Version of Iconic “Plop Plop, Fizz Fizz” Jingle Celebrates Product Providing Relief for the Morning After

WHIPPANY, N.J.--(BUSINESS WIRE)--Oh, what a relief it is! Alka-Seltzer®, the Bayer brand known for its effervescent antacid and pain relief products, today announced a partnership with musician and producer T-Pain to launch its newest innovation, NEW Alka-Seltzer Hangover Relief. After a night with drinking, NEW Alka-Seltzer Hangover Relief provides fast relief from headaches, body aches and mental fatigue the morning after. To introduce the brand to a new set of younger consumers and keep everyone celebrating without fear of the next day, Alka-Seltzer released a remixed version of its iconic “Plop Plop, Fizz Fizz” jingle – mixed, produced and recorded by rapper, musician and cocktail enthusiast, T-Pain.

“My music is inspired by my love of a good drink, and to say I’m excited that there’s a product that works to relieve my symptoms the next morning would be an understatement,” said T-Pain. “And what better way to celebrate than by writing a song about it? Everyone’s had the original jingle stuck in their heads on replay before, but now remixed with fresh and modern sound, today’s listeners will have a new anthem for the morning after.”

The original Alka-Seltzer jingle was released in 1951 with its catchy tune and memorable tagline of “plop, plop, fizz, fizz – oh, what a relief it is” that soon became synonymous with the brand for years to come. T-Pain’s new version of the jingle plays homage to the classic with a spin that, while making it more relevant to the times, still lets consumers know it’s distinctly an Alka-Seltzer product. The jingle is available to stream on AlkaSeltzer.com, and to celebrate, fans are invited to take part in a TikTok dance challenge, showing off their best moves to the remix alongside T-Pain.

“Alka-Seltzer is synonymous with providing fast relief and our latest innovation continues to deliver on that benefit for consumers. Our Hangover Relief product helps consumers pop back fast from their worst hangovers, and there is no one better equipped to help deliver that message than T-Pain,” said David Ball, General Manager & Vice President, Digestive Health, Bayer Consumer Health. “With this new product, we’re taking the fear out of that dreaded morning-after-a-few-drinks feeling so that people can go enjoy themselves knowing we’ve got their backs, while providing an entertaining way to engage with a younger audience through the reimagining of the iconic Alka-Seltzer jingle, “plop plop, fizz fizz – oh, what a relief it is.”

NEW Alka-Seltzer Hangover Relief is available now at retailers nationwide including Target, CVS, Rite Aid, and more. To leave last night in the past with NEW Alka-Seltzer Hangover Relief, simply drop two of the convenient, easy-to-take “orange fizz” flavored tablets in a glass of water for fast relief you can hear, see and feel working due to its combination of extra strength aspirin with caffeine. Use as directed.

To listen to the jingle remix, duet with T-Pain and see behind-the-scenes footage of the jingle remix, visit AlkaSeltzer.com and follow along on the brand’s Instagram and TikTok.

About Alka-Seltzer®

Alka-Seltzer® provides amazingly fast relief for when you need to skip to the good part with a broad range of products treating everything from heartburn to headaches and hangover.

For more information, please visit www.alkaseltzer.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.us or visit us on Facebook, Twitter and Instagram.

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Contacts

Danielle K. Goonan
Senior Director, Strategic Communications, Brand PR, Social and Influencer
Mobile: +1.973.715.7299

Bayer


Release Versions

Contacts

Danielle K. Goonan
Senior Director, Strategic Communications, Brand PR, Social and Influencer
Mobile: +1.973.715.7299

More News From Bayer

Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America, with Bayer donating 1 million meals* through Feeding America®. The campaign kicks off May 14–16 in California with a Walmart community food drive in Clovis, followed by additional food collection at Farm Tour stops in Clovis and Elk Grove. In partnership with Central California Food Bank and Sacr...

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evuzamitide.1,5 The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of...

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic R...
Back to Newsroom